Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Phase 2

Not yet recruiting

Conditions: Acute Leukemia of Ambiguous Lineage

Interventions: Drug: vincristine
Drug: daunorubicin
Drug: cyclophosphamide
Drug: L-Asparaginase
Drug: prednisone
Drug: mercaptopurine
Drug: methotrexate
Drug: dexamethasone
Drug: Tyrosine kinase inhibitor

First Posted Date: 2020-06-19

Last Posted Date: 2020-06-19

Lead Sponsor: wang, jianxiang

Target Recruit Count: 50

Registration Number: NCT04440267

Locations: 🇨🇳
HBDH, Tianjin, Tianjin, China

Oral Dexamethasone as an Intervention for Postoperative Pain and Nausea Management in Total Knee Arthroplasty

Phase 4

Not yet recruiting

Conditions: Postoperative Nausea
Arthritis Knee
Postoperative Pain

Interventions: Drug: Placebo
Drug: Dexamethasone

First Posted Date: 2020-06-16

Last Posted Date: 2020-06-16

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 300

Registration Number: NCT04432259

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Phase 2

Conditions: Tumor
Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: 5-HT3 receptor antagonist
Drug: Megestrol
Drug: dexamethasone

First Posted Date: 2020-06-12

Last Posted Date: 2020-06-12

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT04430361

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

KRDI in Transplant-Eligible MM

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Isatuximab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2020-06-12

Last Posted Date: 2024-12-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT04430894

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM

Phase 2

Recruiting

Conditions: Multiple Myeloma, Refractory

Interventions: Drug: Selinexor
Drug: Dexamethasone
Drug: Bortezomib
Drug: Pomalidomide

First Posted Date: 2020-06-04

Last Posted Date: 2024-03-04

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 141

Registration Number: NCT04414475

Locations: 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇬🇷
Theageneion Cancer Hospital, Thessaloniki, Greece
🇮🇱
Rabin Medical Center (Beilinson Hospital), Petah Tikva, Israel

and more 13 locations

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

Phase 2

Terminated

Conditions: RRMM

Interventions: Drug: Melphalan
Drug: Dexamethasone

First Posted Date: 2020-06-02

Last Posted Date: 2023-03-09

Lead Sponsor: Oncopeptides AB

Target Recruit Count: 27

Registration Number: NCT04412707

Locations: 🇺🇦
Public Non-Profit Enterprise "Kyiv City Clinical Hospital #9" under the Executive Body of Kyiv City Council, Hematology Department #1, Kyiv, Ukraine
🇨🇿
University Hospital Olomouc, Clinic of Hemato-Oncology, Olomouc, Czechia
🇧🇬
Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Sofia, Bulgaria

and more 7 locations